Definitive Healthcare (DH) 27th Annual Needham Growth Conference summary
Event summary combining transcript, slides, and related documents.
27th Annual Needham Growth Conference summary
3 Feb, 2026Business overview and strategy
Focuses on mapping the U.S. healthcare system with proprietary data and analytics, serving customers aiming to sell or compete in healthcare.
Expanded from core reference data to include third-party insights and analytics, targeting a $10 billion TAM.
Recent leadership changes brought a focus on product and go-to-market reinvigoration, emphasizing modern data delivery and distribution partnerships.
Unified platform development is underway to integrate acquired products, aiming for a common UI/UX and streamlined access.
Simplification and acceleration of master data management and digital activation initiatives are prioritized.
Market dynamics and competitive landscape
Faces competition from large platform players bundling data and point solution providers competing on price.
Value-based selling and deep healthcare domain expertise are key differentiators, with interoperability across platforms.
Sales cycles have lengthened due to more complex buying processes and increased involvement from risk, compliance, and finance departments.
M&A in the industry can both create opportunities and lead to vendor rationalization, depending on the acquiring organization’s philosophy.
Sales, go-to-market, and operational changes
Sales force restructured for directness and simplicity, reducing handoffs and aligning compensation with customer success.
New compensation and onboarding processes were collaboratively developed and launched, aiming for better continuity and customer engagement.
KPIs and dashboards are being aligned with operational management, focusing on lead creation, pipeline tracking, and predictive analytics.
Resource allocation is increasingly data-driven, with vertical-specific ROI analysis guiding spend and focus.
Latest events from Definitive Healthcare
- Q4 and full year 2025 beat guidance, but goodwill impairments led to large net losses.DH
Q4 202526 Feb 2026 - Q2 revenue up 5% and adjusted EBITDA up 21%, but net loss from $363.6M goodwill impairment.DH
Q2 20242 Feb 2026 - AI-driven analytics and self-service tools fuel growth, with strong cash flow enabling M&A and buybacks.DH
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - New leadership drives customer focus, platform integration, and disciplined growth initiatives.DH
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue beat guidance, but net loss deepened on a $228.2M goodwill impairment.DH
Q3 202415 Jan 2026 - Strategic focus on data, integration, and innovation is driving retention and new growth channels.DH
28th Annual Needham Growth Conference Virtual14 Jan 2026 - Turnaround strategy leverages data partnerships, operational changes, and cost actions for 2025-26 growth.DH
Raymond James & Associates’ 46th Annual Institutional Investors Conference 20256 Jan 2026 - Q4 results topped guidance, but churn and revenue pressure persist, especially in life sciences.DH
Q4 20241 Dec 2025 - Annual meeting covers director elections, auditor ratification, and executive pay, with strong governance.DH
Proxy Filing1 Dec 2025